LT3377500T - Oksadiazaspiro junginiai, skirti piktnaudžiavimo narkotikais arba priklausomybės nuo jų gydymui - Google Patents
Oksadiazaspiro junginiai, skirti piktnaudžiavimo narkotikais arba priklausomybės nuo jų gydymuiInfo
- Publication number
- LT3377500T LT3377500T LTEPPCT/EP2016/001907T LT16001907T LT3377500T LT 3377500 T LT3377500 T LT 3377500T LT 16001907 T LT16001907 T LT 16001907T LT 3377500 T LT3377500 T LT 3377500T
- Authority
- LT
- Lithuania
- Prior art keywords
- addiction
- treatment
- drug abuse
- oxadiazaspiro
- compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/34—Tobacco-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Addiction (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15382566 | 2015-11-16 | ||
PCT/EP2016/001907 WO2017084752A1 (en) | 2015-11-16 | 2016-11-15 | Oxadiazaspiro compounds for the treatment of drug abuse and addiction |
Publications (1)
Publication Number | Publication Date |
---|---|
LT3377500T true LT3377500T (lt) | 2022-12-12 |
Family
ID=54707728
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
LTEPPCT/EP2016/001907T LT3377500T (lt) | 2015-11-16 | 2016-11-15 | Oksadiazaspiro junginiai, skirti piktnaudžiavimo narkotikais arba priklausomybės nuo jų gydymui |
Country Status (30)
Country | Link |
---|---|
US (2) | US10927128B2 (lt) |
EP (1) | EP3377500B1 (lt) |
JP (1) | JP6884974B2 (lt) |
KR (1) | KR20180080327A (lt) |
CN (1) | CN108349999A (lt) |
AR (1) | AR106697A1 (lt) |
AU (1) | AU2016356488B2 (lt) |
BR (1) | BR112018009279A8 (lt) |
CA (1) | CA3002286A1 (lt) |
CO (1) | CO2018004665A2 (lt) |
DK (1) | DK3377500T3 (lt) |
ES (1) | ES2932000T3 (lt) |
HR (1) | HRP20221343T1 (lt) |
HU (1) | HUE060275T2 (lt) |
IL (1) | IL259035B (lt) |
LT (1) | LT3377500T (lt) |
MA (1) | MA43250B1 (lt) |
MX (1) | MX2018005439A (lt) |
MY (1) | MY193423A (lt) |
PH (1) | PH12018500814A1 (lt) |
PL (1) | PL3377500T3 (lt) |
PT (1) | PT3377500T (lt) |
RS (1) | RS63734B1 (lt) |
SG (1) | SG11201803153RA (lt) |
SI (1) | SI3377500T1 (lt) |
TN (1) | TN2018000122A1 (lt) |
TW (1) | TWI756196B (lt) |
UA (1) | UA123775C2 (lt) |
WO (1) | WO2017084752A1 (lt) |
ZA (1) | ZA201802845B (lt) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT3377500T (pt) | 2015-11-16 | 2022-11-25 | Esteve Pharmaceuticals Sa | Compostos de oxadiazaspiro para o tratamento de abuso e adição a drogas |
WO2020157026A1 (en) * | 2019-01-28 | 2020-08-06 | Esteve Pharmaceuticals, S.A. | Hydroxylated derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain |
AU2022346825A1 (en) | 2021-09-20 | 2024-03-07 | Esteve Pharmaceuticals, S.A. | Oxadiazaspiro compounds for use in the treatment of motoneuron degeneration or in neuroprotection |
WO2024105225A1 (en) | 2022-11-18 | 2024-05-23 | Universitat De Barcelona | Synergistic combinations of a sigma receptor 1 (s1r) antagonist and a soluble epoxide hydrolase inhibitor (sehi) and their use in the treatment of pain |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4244961A (en) * | 1978-10-26 | 1981-01-13 | Syntex (U.S.A.) Inc. | 1-Oxa-3,8-diazaspiro[4.5]decan-2-ones antihypertensive agents |
US4332804A (en) | 1981-03-23 | 1982-06-01 | Syntex (U.S.A.) Inc. | 9-[2-(3-Indolyl)ethyl]-1oxa-4,9-diazaspiro[5.5]undecan-3-ones |
US4353900A (en) * | 1981-10-19 | 1982-10-12 | Syntex (U.S.A.) Inc. | 9-(Arylalkyl or aroylalkyl)-1-oxa-4,9-diazaspiro(5.5)undecan-3-ones |
US4353901A (en) * | 1981-10-19 | 1982-10-12 | Syntex (U.S.A.) Inc. | 9-(1,4-Benzodioxan-2-ylalkyl and hydroxyalkyl)-1-oxa-4,9-diazaspiro[5.5]undecan-3-ones |
US6114541A (en) | 1997-03-10 | 2000-09-05 | Hoffmann-La Roche Inc. | Method for the preparation of α-Bromo-Lactam derivatives |
WO2005075484A2 (en) * | 2004-02-10 | 2005-08-18 | F. Hoffmann-La Roche Ag | Chemokine ccr5 receptor modulators |
CA2557354C (en) | 2004-03-03 | 2013-05-07 | Vital Health Sciences Pty Ltd. | Alkaloid formulations |
WO2006022454A1 (ja) * | 2004-08-27 | 2006-03-02 | Ono Pharmaceutical Co., Ltd | 塩基性基を含有する化合物およびその用途 |
EP1634873A1 (en) | 2004-08-27 | 2006-03-15 | Laboratorios Del Dr. Esteve, S.A. | Sigma receptor inhibitors |
CN101228127B (zh) * | 2005-05-30 | 2012-05-16 | Msdk.K.公司 | 哌啶衍生物 |
CN101203567A (zh) * | 2005-06-07 | 2008-06-18 | 西巴特殊化学品控股有限公司 | 抗刮擦聚烯烃 |
DE102005030051A1 (de) | 2005-06-27 | 2006-12-28 | Grünenthal GmbH | Substituierte 1-Oxa-3,8-diazaspiro[4,5]-decan-2-on-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln |
EP2388258A1 (de) | 2005-10-19 | 2011-11-23 | Grünenthal GmbH | Neue Vanilloidrezeptor-Liganden und ihre Verwendung zur Herstellung von Arzneimitteln |
PL1961744T3 (pl) | 2005-11-18 | 2013-09-30 | Ono Pharmaceutical Co | Związek zawierający grupę zasadową oraz jego zastosowanie |
EP1829869A1 (en) | 2006-03-02 | 2007-09-05 | Laboratorios Del Dr. Esteve, S.A. | 4,5,6,7-Tetrahydrobenzo[b]thiophene derivatives and their use as sigma receptor ligands |
EP1847542A1 (en) | 2006-04-21 | 2007-10-24 | Laboratorios del Dr. Esteve S.A. | Spiro[benzopyran] or spiro[benzofuran] derivatives which inhibit the sigma receptor |
JP5313865B2 (ja) | 2007-03-01 | 2013-10-09 | 田辺三菱製薬株式会社 | ベンゾイミダゾール化合物およびその医薬用途 |
EP1982714A1 (en) | 2007-04-16 | 2008-10-22 | Laboratorios del Dr. Esteve S.A. | Pyrano-pyrazole-amines |
EP2020414A1 (en) | 2007-06-20 | 2009-02-04 | Laboratorios del Dr. Esteve S.A. | spiro[piperidine-4,4'-thieno[3,2-c]pyran] derivatives and related compounds as inhibitors of the sigma receptor for the treatment of psychosis |
US20110190280A1 (en) | 2007-08-29 | 2011-08-04 | George Adjabeng | Thiazole And Oxazole Kinase Inhibitors |
EP2070933A1 (en) | 2007-12-07 | 2009-06-17 | Laboratorios del Dr. Esteve S.A. | Tricyclic triazolic compounds |
KR101273200B1 (ko) | 2008-02-06 | 2013-06-17 | 펄마젠 쎄라퓨틱스 (시너지) 리미티드 | 화합물 |
EP2108643A1 (en) * | 2008-04-10 | 2009-10-14 | Laboratorios Del. Dr. Esteve, S.A. | 4-methyl-4, 5-dihydro-1H-pyrazole-3-carboxamide useful as a cannabinoid CB1 neutral antagonist |
GB201016912D0 (en) * | 2010-10-07 | 2010-11-24 | Astrazeneca Ab | Novel combination |
CN103517910B (zh) | 2011-03-14 | 2016-12-14 | 沃泰克斯药物股份有限公司 | 作为离子通道调节剂的吗啉-螺环哌啶酰胺 |
GB201107985D0 (en) | 2011-05-13 | 2011-06-29 | Astrazeneca Ab | Process |
WO2013052716A1 (en) * | 2011-10-07 | 2013-04-11 | Glaxosmithkline Llc | Fatty acid synthase inhibitors |
WO2013115294A1 (ja) * | 2012-01-31 | 2013-08-08 | 東レ株式会社 | ジアザスピロウレア誘導体及びその医薬用途 |
EP3027625B1 (en) | 2013-07-31 | 2018-05-30 | Merck Sharp & Dohme Corp. | Spiro-fused derivatives of piperidine useful for the treatment of inter alia hypertension and acute or chronic heart failure |
TW201615643A (zh) * | 2014-06-02 | 2016-05-01 | 伊史帝夫博士實驗室股份有限公司 | 具有多重模式抗疼痛活性之1-氧雜-4,9-二氮雜螺十一烷化合物之烷基與芳基衍生物 |
TWI685497B (zh) * | 2014-06-02 | 2020-02-21 | 西班牙商伊史帝夫製藥公司 | 具有多重模式抗疼痛活性的1-氧雜-4,9-二氮雜螺十一烷化合物之烷基衍生物 |
TW201615642A (zh) | 2014-06-02 | 2016-05-01 | 伊史帝夫博士實驗室股份有限公司 | 具有多重模式抗疼痛活性的1-氧雜-4,9-二氮雜螺十一烷化合物之醯胺衍生物 |
US10513518B2 (en) * | 2015-01-29 | 2019-12-24 | Merck Sharp & Dohme Corp. | Inhibitors of the renal outer medullary potassium channel |
PT3377500T (pt) | 2015-11-16 | 2022-11-25 | Esteve Pharmaceuticals Sa | Compostos de oxadiazaspiro para o tratamento de abuso e adição a drogas |
-
2016
- 2016-11-15 PT PT167974583T patent/PT3377500T/pt unknown
- 2016-11-15 HR HRP20221343TT patent/HRP20221343T1/hr unknown
- 2016-11-15 US US15/774,407 patent/US10927128B2/en active Active
- 2016-11-15 MA MA43250A patent/MA43250B1/fr unknown
- 2016-11-15 CA CA3002286A patent/CA3002286A1/en active Pending
- 2016-11-15 ES ES16797458T patent/ES2932000T3/es active Active
- 2016-11-15 JP JP2018524257A patent/JP6884974B2/ja active Active
- 2016-11-15 PL PL16797458.3T patent/PL3377500T3/pl unknown
- 2016-11-15 AR ARP160103486A patent/AR106697A1/es unknown
- 2016-11-15 EP EP16797458.3A patent/EP3377500B1/en active Active
- 2016-11-15 LT LTEPPCT/EP2016/001907T patent/LT3377500T/lt unknown
- 2016-11-15 TN TNP/2018/000122A patent/TN2018000122A1/en unknown
- 2016-11-15 BR BR112018009279A patent/BR112018009279A8/pt active IP Right Grant
- 2016-11-15 SI SI201631621T patent/SI3377500T1/sl unknown
- 2016-11-15 MY MYPI2018701503A patent/MY193423A/en unknown
- 2016-11-15 KR KR1020187017092A patent/KR20180080327A/ko not_active Application Discontinuation
- 2016-11-15 HU HUE16797458A patent/HUE060275T2/hu unknown
- 2016-11-15 WO PCT/EP2016/001907 patent/WO2017084752A1/en active Application Filing
- 2016-11-15 SG SG11201803153RA patent/SG11201803153RA/en unknown
- 2016-11-15 MX MX2018005439A patent/MX2018005439A/es unknown
- 2016-11-15 CN CN201680066748.9A patent/CN108349999A/zh active Pending
- 2016-11-15 DK DK16797458.3T patent/DK3377500T3/da active
- 2016-11-15 TW TW105137236A patent/TWI756196B/zh active
- 2016-11-15 UA UAA201806353A patent/UA123775C2/uk unknown
- 2016-11-15 AU AU2016356488A patent/AU2016356488B2/en active Active
- 2016-11-15 RS RS20221052A patent/RS63734B1/sr unknown
-
2018
- 2018-04-16 PH PH12018500814A patent/PH12018500814A1/en unknown
- 2018-04-30 IL IL259035A patent/IL259035B/en active IP Right Grant
- 2018-04-30 ZA ZA2018/02845A patent/ZA201802845B/en unknown
- 2018-04-30 CO CONC2018/0004665A patent/CO2018004665A2/es unknown
-
2020
- 2020-12-21 US US17/128,738 patent/US11649248B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL258931A (en) | Medicinal compounds and methods | |
HK1247614A1 (zh) | 治療化合物及其用途 | |
IL266674A (en) | Preparations and methods for treating an opioid overdose | |
HK1258276A1 (zh) | 用於治療hiv的化合物和組合 | |
IL262825A (en) | Tetrahydropyridine and tetrahydropyrimidine substances, preparations containing them and their use for pain treatment | |
ZA201606322B (en) | Methods for acute and long-term treatment of drug addiction | |
GB201608885D0 (en) | Treatment | |
HK1248697A1 (zh) | 治療化合物及其用途 | |
ZA201802256B (en) | Compounds and therapeutic uses thereof | |
GB201617064D0 (en) | Compounds and their therapeutic use | |
ZA201802845B (en) | Oxadiazaspiro compounds for the treatment of drug abuse and addiction | |
IL270011B (en) | Medicinal compounds and methods | |
GB201504387D0 (en) | Materials and methods for the treatment of vascular disease | |
HK1255695A1 (zh) | 用於治療眼瞼下垂的組合物和方法 | |
RS63872B1 (sr) | Derivati citizina za lečenje zavisnosti | |
IL266866A (en) | A drug to treat ***e addiction or prevent its relapse | |
HK1257593A1 (zh) | 治療糖尿病的新藥物及其用途 | |
IL260091A (en) | Composition and a method of treatment of the physical addiction | |
GB201608599D0 (en) | Treatment of opioid tollerence | |
GB201617107D0 (en) | Treatment | |
GB201613350D0 (en) | Treatment of hyperpigmentation | |
GB201612260D0 (en) | Treatment | |
GB201612193D0 (en) | Treatment | |
GB201609683D0 (en) | Treatment | |
GB201523012D0 (en) | The combination of chinese medicine for treating infantile cough |